CTOs on the Move

IO Biotech

www.iobiotech.com

 
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase. IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.iobiotech.com
  • 430 East 29th Street Suite 940
    New York, NY USA 10016
  • Phone: 646.440.9310

Executives

Name Title Contact Details

Similar Companies

Clemson University Biomedical Engineering Innovation Campus

The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.

Emiliem Inc

Emiliem Inc is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BridgeBio

We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.

Targacept

Targacept`s clinical pipeline is built on a unique class of therapeutic targets.

Metagenomi

Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.